• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    (NY: KVUE )

    22.73 -0.20 (-0.87%)
    Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about KVUE

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    16 17 Next >
    Neutrogena® Launches Breakthrough Collaboration with Two of World’s Most Recognizable Dermatologists
    From Kenvue
    Via Business Wire
    This Big New Development Could Be Bullish for Kenvue Stock
    Can tinkering around the edges actually make this stock more attractive? 
    Via The Motley Fool
    3 Dividend Stocks to Double Up on Right Now
    While tech-based growth stocks might seem like the right play, you can't ignore dividends if you want to have a strong portfolio. 
    Via The Motley Fool
    Billionaire Ken Griffin Just Increased His Position in This Dividend Stock by 5,848%. Here's Why Now May Be a Great Time to Buy.
    Ken Griffin's Citadel just added 18 million shares of an under-the-radar consumer health stock. 
    Via The Motley Fool
    Meet the 3.6%-Yielding Dividend King Stock That's Up 25% in 3 Months
    An activist investor is taking a stake in Kenvue stock. 
    Via The Motley Fool
    Is Kenvue Stock a Buy Now?
    The growth rate of the consumer healthcare business could accelerate now that an activist investor is involved. 
    Via The Motley Fool
    10 Analysts Have This To Say About Kenvue
    Via Benzinga
    Navigating 10 Analyst Ratings For Kenvue
    Via Benzinga
    Starboard Hammers Pfizer Execs For Failing To Deliver On 'Best Pipeline' Promises
    The activist investor says Pfizer has underperformed its peers and the broader market since 2019. 
    Via Investor's Business Daily
    Nvidia Among Five Best S&P 500 Stocks Today
    Pfizer spinoff Kenvue led the S&P 500 on Monday. Nvidia was close behind. 
    Via Investor's Business Daily
    Topics Stocks
    Exposures US Equities
    Dow Drops 320 Points as Stocks Cool Off
    Stocks are stumbling out of the gate this week. 
    Via Talk Markets
    Topics Stocks
    Exposures US Equities
    What's Going On With Kenvue Stock Monday?
    Kenvue Inc. (NYSE:KVUE) shares are moving higher Monday following a report suggesting activist investor Starboard Value has acquired a stake in the company. 
    Via Benzinga
    Stocks Fall As Treasury Yields, Dollar Rise; Nvidia Hits Record Highs: What's Driving Markets Monday?
    U.S. major indices fell on Monday as rising Treasury yields and a strengthening dollar dampened risk sentiment. Investors are reassessing the economic outlook and weighing potential risks tied to the... 
    Via Benzinga
    P/E Ratio Insights for Kenvue
    Via Benzinga
    There are signs that NYSE:KVUE may be ready to breakout.
    KENVUE INC is setting up nicely for a breakout. 
    Via Chartmill
    Starboard Value Buys Into Dow Jones Spinoff; Elf Beauty Rallies
    Elf Beauty appeared to rally along with KVUE on Monday. 
    Via Investor's Business Daily
    Topics Stocks
    Exposures US Equities
    Activist Investor Starboard Acquires Stake In Band-Aid Maker Kenvue, Shares Jump
    Activist hedge fund Starboard Value has reportedly taken a stake in Kenvue, sparking a pre-market stock surge. 
    Via Talk Markets
    Tylenol, Listerine Maker Kenvue Under Activist Spotlight With Starboard Value Stake — Overhaul Ahead For The Johnson & Johnson Spinoff?
    Starboard Value, an activist investor, has reportedly acquired a substantial stake in Kenvue Inc, the company behind popular consumer products like Tylenol and Listerine. 
    Via Benzinga
    Kenvue to Announce Third Quarter 2024 Results on November 7, 2024
    From Kenvue
    Via Business Wire
    Kenvue Declares Quarterly Cash Dividend
    From Kenvue
    Via Business Wire
    Analyst Ratings For Kenvue
    Via Benzinga
    Johnson & Johnson Stock: Setting the Stage for 2025 Highs
    Healthcare giant and Dividend Aristocrat Johnson & Johnson is on track to hit new highs in 2025 and may sustain its rally well into 2026. 
    Via MarketBeat
    Exposures COVID-19
    All It Takes Is $1,000 Invested in Each of These 3 Dividend Kings to Help Generate Over $100 in Passive Income Per Year
    Target, PepsiCo, and Kenvue have high yields and inexpensive valuations. 
    Via The Motley Fool
    World's Third-Largest OTC Player Sanofi's Consumer Health Unit Nears $16B Deal With Clayton Dubilier & Rice
    Sanofi is negotiating a potential sale of a 50% stake in its consumer health unit, Opella, to Clayton Dubilier & Rice. The deal, valued at $16.4 billion, could help Sanofi sharpen its focus on... 
    Via Benzinga
    Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff
    Sanofi plans to spin off its consumer healthcare division, which could be valued at over $16.8 billion. Private equity firms are bidding for the unit, with the spinoff expected by Q4 2024. Banks... 
    Via Benzinga
    Kenvue Drives Climate Action Strategy Forward
    From Kenvue
    Via Business Wire
    Kenvue Set To Pop Like A Tylenol Gelcap? Golden Cross Looms On Stock Chart
    Kenvue Inc., owner of major brands like Tylenol, is poised for a technical knockout with a Golden Cross pattern and legal win. 
    Via Benzinga
    Worried About a Stock Market Sell-Off? Consider Coca-Cola, Pepsi, and These 3 Safe Dividend Kings for Decades of Passive Income.
    Via The Motley Fool
    Magnificent 7 Miss Out, 2 Cybersecurity Stocks Stand Firm, Retailers Lag In Volatile August: Here Are The Top S&P 500 Gainers And Losers
    The equity market was volatile in August, with the weakness seen early in the month dissipating amid a rise in rate-cut bets. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Johnson & Johnson-Spin Off Kenvue Wins Lawsuit Over Pain Killer Tylenol 'Rapid Release' Gelcaps
    Kenvue defends against a consumer lawsuit alleging that its Tylenol "Rapid Release" gelcaps did not relieve pain faster than regular tablets. A federal judge ruled the claims were preempted by FDA... 
    Via Benzinga
    Topics Lawsuit
    Exposures Financial Legal Product Safety
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    16 17 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.